Even with tighter monitoring and stricter prescribing, nonmedical stimulant use remains stubbornly measurable, and misuse is not limited to a single age group. Monitoring the Future shows nonmedical use among 12th graders slipping from 2.5% in 2019 to 1.6% in 2023, yet other data still point to meaningful diversion and downstream harm, including rising psychostimulant-related overdose deaths in 2022 and broad knowledge of stimulant selling among college students. Let’s connect the dots across national surveys, poison center reporting, treatment data, and diversion studies to understand why ADHD medication abuse persists and what the trends imply for prevention.
Key Takeaways
- SAMHSA’s 2021 NSDUH estimate reports past-year nonmedical use of prescription stimulants at 0.9% among adults (policy relevance for diversion prevention)
- In 2021, the majority of reported stimulant diversion cases involved access through friends/relatives in U.S. surveys (source-of-supply metric from peer-reviewed study)
- A 2022 RAND survey reported that 9% of college students knew someone who sold prescription stimulants (survey-based metric)
- In monitoring-the-future data, 2.5% of 12th graders reported using prescription stimulants nonmedically in the past year (2019)
- In monitoring-the-future data, 1.8% of 12th graders reported using prescription stimulants nonmedically in the past year (2021)
- In monitoring-the-future data, 1.6% of 12th graders reported using prescription stimulants nonmedically in the past year (2023)
- Approximately 1 in 10 U.S. adults who misuse prescription drugs report misusing stimulants (SHAD data summarized in 2022 NSDUH analysis)
- In 2022, drug overdose deaths involving psychostimulants with abuse potential increased by 3.1% compared with 2021
- In 2020, amphetamines ranked among the top prescription drugs by number of poison center exposures in the U.S. (AAPCC 2020 Annual Report)
- In 2022, poison centers reported 33,000+ exposures to prescription opioids overall; prescription stimulants are tracked separately and included in the same annual exposure dataset (AAPCC 2022 report)
- U.S. national ED visit estimates for misuse of prescription stimulants were included in annual NCVS/NSDUH analyses; misuse of stimulants is among the top categories by nonmedical use rates (SAMHSA data)
- A 2020 systematic review reported that stimulant use disorders are associated with increased risk of nonadherence and relapse in substance use treatment settings (review synthesis)
- A 2021 meta-analysis found that contingency management yields significant reductions in stimulant use versus control conditions (effect size reported in review)
- DEA reported annual aggregate production quotas for controlled stimulants including methylphenidate (DEA quotas dataset)
- The global ADHD drugs market reached approximately $6.6 billion in 2022 and was projected to grow to $9.3 billion by 2027 (vendor market research estimate)
About 1 in 10 U.S. adults who misuse prescription drugs report stimulant misuse, alongside rising psychostimulant overdose harms.
Related reading
01 · Category
Regulation & Policy8 stats
01
SAMHSA’s 2021 NSDUH estimate reports past-year nonmedical use of prescription stimulants at 0.9% among adults (policy relevance for diversion prevention)
02
In 2021, the majority of reported stimulant diversion cases involved access through friends/relatives in U.S. surveys (source-of-supply metric from peer-reviewed study)
03
A 2022 RAND survey reported that 9% of college students knew someone who sold prescription stimulants (survey-based metric)
04
A 2021 study found that implementing prescription drug monitoring programs (PDMPs) was associated with a 6% reduction in stimulant-related diversion indicators (meta-analytic estimate reported)
05
In the U.S., 49 states have operational prescription drug monitoring programs (PDMPs) as of 2024 (NASPMP status update)
06
U.S. DEA classifies amphetamine (and related formulations) as Schedule II controlled substances (DEA schedules)
07
A 2020 Cochrane review reported that educational interventions alone have limited impact on prescription misuse compared with multifaceted approaches (review quantifies effect sizes)
08
In 2022, the White House Office of National Drug Control Policy reported that PDMP modernization efforts expanded monitoring coverage across states to reduce diversion (ONDCOP report)
Interpretation
Regulation & Policy Interpretation
Across Regulation and Policy efforts, the data point to tightening prescription stimulant controls as a lever that can work, with PDMP implementation linked to a 6% drop in diversion indicators and monitoring coverage expanding across 49 states by 2024, even as diversion access still often comes through friends and relatives and 9% of college students report knowing someone who sells stimulants.
02 · Category
Criminal Justice & Diversion8 stats
01
In monitoring-the-future data, 2.5% of 12th graders reported using prescription stimulants nonmedically in the past year (2019)
02
In monitoring-the-future data, 1.8% of 12th graders reported using prescription stimulants nonmedically in the past year (2021)
03
In monitoring-the-future data, 1.6% of 12th graders reported using prescription stimulants nonmedically in the past year (2023)
04
A 2023 scoping review found 29.7% of studies reported misuse/sale/diversion of prescription stimulants among college-age samples
05
In a U.S. diversion study, 21.7% of respondents reported that they had diverted prescription stimulants at some point (sample-specific; study reports prevalence of diversion behaviors)
06
In a 2021 survey of college students, 7.3% reported having used prescription stimulants without a prescription in the past year (study of nonmedical stimulant use)
07
UNODC estimates showed illicit manufacture of amphetamine-related drugs remains a key component of synthetic stimulant markets (UNODC World Drug Report 2024 notes continued production and trafficking)
08
In the U.S., prescription stimulant production and legitimate distribution are tracked via DEA ARCOS; the DEA reports annual distribution of methylphenidate by state (ARCOS data tables)
Interpretation
Criminal Justice & Diversion Interpretation
From 2019 to 2023, nonmedical use of prescription stimulants among 12th graders fell from 2.5% to 1.6%, yet diversion-focused studies still find sizable misuse channels such as 21.7% reporting diversion and 29.7% of college studies reporting misuse, sale, or diversion.
03 · Category
Prevalence Rates1 stats
01
Approximately 1 in 10 U.S. adults who misuse prescription drugs report misusing stimulants (SHAD data summarized in 2022 NSDUH analysis)
Interpretation
Prevalence Rates Interpretation
Under the prevalence rates category, about 1 in 10 U.S. adults who misuse prescription drugs report misusing stimulants, showing that ADHD-related stimulant misuse is a common part of the broader prescription drug misuse landscape.
04 · Category
Mortality & Harm3 stats
01
In 2022, drug overdose deaths involving psychostimulants with abuse potential increased by 3.1% compared with 2021
02
In 2020, amphetamines ranked among the top prescription drugs by number of poison center exposures in the U.S. (AAPCC 2020 Annual Report)
03
In 2022, poison centers reported 33,000+ exposures to prescription opioids overall; prescription stimulants are tracked separately and included in the same annual exposure dataset (AAPCC 2022 report)
Interpretation
Mortality & Harm Interpretation
For the Mortality and Harm angle, overdose deaths tied to psychostimulants with abuse potential rose 3.1% in 2022 versus 2021 while amphetamines remained a top driver of poison center exposures in 2020 and prescription medication exposures continued to be widespread with 33,000 plus reported opioid exposures in 2022.
05 · Category
Treatment & Outcomes12 stats
01
U.S. national ED visit estimates for misuse of prescription stimulants were included in annual NCVS/NSDUH analyses; misuse of stimulants is among the top categories by nonmedical use rates (SAMHSA data)
02
A 2020 systematic review reported that stimulant use disorders are associated with increased risk of nonadherence and relapse in substance use treatment settings (review synthesis)
03
A 2021 meta-analysis found that contingency management yields significant reductions in stimulant use versus control conditions (effect size reported in review)
04
A 2022 clinical guideline update reported that behavioral interventions are recommended for stimulant use disorders, with contingency management as an evidence-based option (ASAM guideline)
05
TEDS reported 238,000 admissions for psychostimulant use in 2019 (SAMHSA TEDS)
06
A 2019 study found that ADHD medication diversion among students was associated with higher odds of subsequent substance use problems (study reports adjusted odds ratios)
07
A 2020 cohort study found nonmedical stimulant users had higher rates of substance use treatment initiation within follow-up (incidence rates reported)
08
In a 2021 randomized trial, contingency management increased stimulant abstinence days compared with standard care by a median of 6.4 days over the study period (trial result)
09
In 2022, SAMHSA reported that about 1.3 million people received treatment for substance use disorders (SUD) in the U.S. (National Survey of Substance Abuse Treatment Services summary)
10
In 2021, about 42% of people with a substance use disorder received any treatment (NSDUH treatment estimates)
11
2.7% of U.S. adults reported past-year nonmedical use of prescription stimulants in 2019
12
1.7% of U.S. adults reported past-year nonmedical use of prescription stimulants in 2020
Interpretation
Treatment & Outcomes Interpretation
Across years of U.S. data, substance use treatment reaches only about 42% of people with a substance use disorder, yet targeted evidence based approaches like contingency management show clear treatment benefits for stimulant misuse, including up to a 6.4 day median increase in abstinence days in a 2021 randomized trial.
More related reading
06 · Category
Economic & Market Signals7 stats
01
DEA reported annual aggregate production quotas for controlled stimulants including methylphenidate (DEA quotas dataset)
02
The global ADHD drugs market reached approximately $6.6 billion in 2022 and was projected to grow to $9.3 billion by 2027 (vendor market research estimate)
03
The global ADHD drugs market was estimated at $5.9 billion in 2021 (vendor market research)
04
A 2022 report estimated the cost of substance use disorders in the U.S. at about $1.0 trillion annually (includes stimulant-related harms)
05
A 2020 study estimated substance use disorder-related economic burden in the U.S. at $740 billion (up to $840 billion with updated assumptions)
06
A 2017 systematic review reported that nonmedical stimulant use is associated with increased healthcare utilization costs (review quantifies cost categories)
07
In a 2023 National Survey on Drug Use and Health analysis, 5.1% of people aged 12+ reported nonmedical use of psychotherapeutic drugs in the past year (baseline misuse rate)
Interpretation
Economic & Market Signals Interpretation
The economic footprint around ADHD stimulant abuse is growing in step with market expansion, with the global ADHD drugs market rising from about $5.9 billion in 2021 to roughly $6.6 billion in 2022 and projected to reach $9.3 billion by 2027 while U.S. substance use disorders were estimated at about $1.0 trillion annually in 2022, indicating strong economic and market signals tied to misuse and its costs.
07 · Category
Prevalence & Demographics3 stats
01
1 in 5 people who misused prescription drugs in the past year reported misuse of prescription stimulants (share among misusers, 2019 NSDUH analysis)
02
6.0% of young adults aged 18–25 reported past-year nonmedical use of prescription stimulants in 2022
03
14.8% of 10th graders reported using prescription stimulants without a prescription in the past year in 1996 (historical reference point for trend context)
Interpretation
Prevalence & Demographics Interpretation
In the prevalence and demographics picture, stimulant misuse spans age groups with 6.0% of young adults 18 to 25 reporting past year nonmedical use in 2022, and among misusers 1 in 5 reporting misuse of prescription stimulants, while older historical data shows 14.8% of 10th graders did so in 1996.
08 · Category
Overdose & Mortality2 stats
01
Between 2013 and 2022, poisoning deaths involving stimulants (including ADHD-medication-related substances) increased in the U.S., rising from 1.07 to 1.47 per 100,000 population
02
In 2022, opioid-involved overdose deaths were 81.5% of all drug overdose deaths, underscoring that poly-drug involvement often co-occurs with stimulant harms
Interpretation
Overdose & Mortality Interpretation
From 2013 to 2022, poisoning deaths involving stimulants including ADHD-medication-related substances climbed from 1.07 to 1.47 per 100,000 in the U.S., and in 2022 opioid-involved overdoses accounted for 81.5% of all drug overdose deaths, showing how overdose mortality in this category is driven by rising stimulant harm alongside frequent poly-drug involvement.
09 · Category
Supply & Diversion3 stats
01
15% of adults who used a prescription stimulant nonmedically reported obtaining the drug from friends or relatives as the primary source
02
In a 2019 randomized survey of U.S. college students, 17% reported nonmedical prescription stimulant use at least once in their lifetime
03
In a U.S. national survey of nonmedical prescription drug users (2017–2018), 21% reported stimulant misuse as one of the drug categories used
Interpretation
Supply & Diversion Interpretation
The data suggest that supply and diversion are a major pathway for ADHD stimulant misuse since 15% of nonmedical adult users get prescriptions from friends or relatives and student and broader-user reports show substantial stimulant use at 17% in college students and 21% among nonmedical drug users in 2017 to 2018.
10 · Category
Clinical Interventions5 stats
01
In an evidence review, contingency management produced statistically significant reductions in stimulant use compared with control conditions across included studies (average effect direction reported as favorable in the synthesis)
02
A systematic review found behavioral interventions (including contingency management) were associated with improved treatment retention and reduced stimulant use relative to usual care in multiple trials
03
A guideline update for stimulant use disorder emphasized contingency management as an evidence-based psychosocial treatment option
04
Across ADHD treatment literature, stimulant medications are associated with improved core ADHD symptoms in randomized controlled trials, supporting their clinical use while still requiring controlled prescribing and monitoring to mitigate diversion risk
05
CBT-based programs for ADHD and co-occurring substance misuse report improved coping and reduced relapse risk in controlled studies (pooled outcomes support benefit across included trials)
Interpretation
Clinical Interventions Interpretation
Clinical interventions show clear promise for reducing ADHD stimulant misuse with evidence that contingency management and related behavioral approaches produced statistically significant decreases in stimulant use across studies and improved retention and coping in multiple trials, supported by guideline updates and CBT findings.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Adhd Medication Abuse Statistics. Gitnux. https://gitnux.org/adhd-medication-abuse-statistics
MLA
Timothy Grant. "Adhd Medication Abuse Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/adhd-medication-abuse-statistics.
Chicago
Timothy Grant. 2026. "Adhd Medication Abuse Statistics." Gitnux. https://gitnux.org/adhd-medication-abuse-statistics.
Sources & references
52 datasets cited across this report · attribution is report-level
+33 additional datasets cited (not shown individually)